Viability screen on pediatric low grade glioma cell lines unveils a novel anti-cancer drug of the steroid biosynthesis inhibitor family

Cancer Letters

Volumn 330, Issue 1, 2013, Pages 96-105

  Ajeawung, Norbert Fonya ^a   Maltais, René ^a   Jones, Chris ^b   Poirier, Donald ^a   Kamnasaran, Deepak ^a,c  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cytotoxicity; Drug discovery; Low grade glioma; Pediatric astrocytomas

Indexed keywords

15B (3ALPHA, 5ALPHA) 3 [[2,5 DIMETHYL 4 [[2 (TRIFLUOROMETHYL)PHENYL]SULFONYL]PIPERAZIN 1 YL]3 HYDROXYANDROSTAN 17 ONE]; APOPTOSIS INDUCING FACTOR; CARMUSTINE; CATHEPSIN L; CATHEPSIN L1; CYCLIN DEPENDENT KINASE 2; GELATINASE A; INTERSTITIAL COLLAGENASE; PHOSPHATIDYLSERINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; STEROID HORMONE ANTAGONIST; STRESS ACTIVATED PROTEIN KINASE 1; TELOMERASE REVERSE TRANSCRIPTASE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 3; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; MATRIX METALLOPEPTIDASE 1 GENE; MATRIX METALLOPEPTIDASE 2 GENE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOGEN ACTIVATED PROTEIN KINASE 8 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN KINASE C ALPHA GENE; PROTEIN SECRETION; STEROIDOGENESIS; TELOMERASE REVERSE TRANSCRIPTASE GENE;

17-HYDROXYSTEROID DEHYDROGENASES; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; HUMANS; NEOPLASM GRADING; STEROIDS;

EID: 84872862926     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.034     Document Type: Article

References (52)

1. Karajannis M., Allen J.C., Newcomb E.W. Treatment of pediatric brain tumors. J. Cell Physiol. 2008, 217:584-589.
2. Gnekow A.K., Kortmann R.D., Pietsch T., Emser A. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy - report from the multicenter treatment study for children and adolescents with a low grade glioma - HIT-LGG 1996 - of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr. 2004, 216:331-342.
3. Bowers D.C., Krause T.P., Aronson L.J., Barzi A., Burger P.C., Carson B.S., Weingart J.D., Wharam M.D., Melhem E.R., Cohen K.J. Second surgery for recurrent pilocytic astrocytoma in children. Pediatr. Neurosurg. 2001, 34:229-234.
4. Fisher P.G., Tihan T., T Goldthwaite P., Wharam M.D., Carson B.S., Weingart J.D., Repka M.X., Cohen K.J., Burger P.C. Outcome analysis of childhood low-grade astrocytomas. Pediatr. Blood Cancer 2008, 51:245-250.
5. Sharif S., Ferner R., Birch J.M., Gillespie J.E., Gattamaneni H.R., Baser M.E., Evans E.G. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J. Clin. Oncol. 2006, 24:2570-2575.
6. Donahue B. Short- and long-term complications of radiation therapy for pediatric brain tumors. Pediatr. Neurosurg. 1992, 18:207-217.
7. Packer R.J., Ater J., Allen J., Phillips P., Geyer R., Nicholson H.S., Jakacki R., Kurczynski E., Needle M., Finlay J., Reaman G., Boyett J.M. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J. Neurosurg. 1997, 86:747-754.
8. Gururangan S., Fisher M.J., Allen J.C., Herndon J.E., Quinn J.A., Reardon D.A., Vredenburgh J.J., Desjardins A., Phillips P.C., Watral M.A., Krauser J.M., Friedman A.H., Friedman H.S. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007, 9:161-168.
9. Perilongo G. Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma. J. Neurooncol. 2005, 75:301-307.
10. Fouladi M., Hunt D.L., Pollack I.F., Dueckers G., Burger P.C., Becker L.E., Yates A.J., Gilles F.H., Davis R.L., Boyett J.M., Finlay J.L. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945. Cancer 2003, 98:1243-1252.
11. Laithier V., Grill J., Le Deley M.C., Ruchoux M.M., Couanet D., Doz F., Pichon F., Rubie H., Frappaz D., Vannier J.P., Babin-Boilletot A., Sariban E., Chastagner P., Zerah M., Raquin M.A., Hartmann O., Kalifa C. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy-results of the first French prospective study for the French Society of Pediatric Oncology. J. Clin. Oncol. 2003, 21:4572-4578.
12. Opocher E., Kremer L.C., Da D.L., van de Wetering M.D., Viscardi E., Caron H.N., Perilongo G. Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur. J. Cancer. 2006, 42:1807-1816.
13. Kabat G.C., Etgen A.M., Rohan T.E. Do steroid hormones play a role in the etiology of glioma?. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2421-2427.
14. Marchais-Oberwinkler S., Henn C., Möller G., Klein T., Negri M., Oster A., Spadaro A., Werth R., Wetzel M., Xu K., Frotscher M., Hartmann R.W., Adamski J. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J. Steroid Biochem. Mol. Biol. 2011, 125:66-82.
15. Lota R.K., Dhanani S., Owen C.P., Ahmed S. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3). Bioorg. Med. Chem. Lett. 2006, 16:4519-4522.
16. Poirier D. Inhibitors of 17β-hydroxysteroid dehydrogenase. Curr. Med. Chem. 2003, 10:453-477.
17. Poirier D. New cancer drugs targeting the biosynthesis of estrogens and androgens. Drug Dev. Res. 2008, 69:304-318.
18. Gatson J.W., Kaur P., Singh M. Dihydrotestosterone differentially modulates the mitogen-activated protein kinase and the phosphoinositide 3-kinase/Akt pathways through the nuclear and novel membrane androgen receptor in C6 cells. Endocrinology 2006, 147:2028-2034.
19. Fox E.M., Andrade J., Shupnik M.A. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009, 74:622-627.
20. Hamzeh M., Robaire B. Androgens activate mitogen-activated protein kinase via epidermal growth factor receptor/insulin-like growth factor 1 receptor in the mouse PC-1 cell line. J. Endocrinol. 2011, 209:55-64.
21. Robaire B., Hamzeh M. Androgen action in the epididymis. J. Androl. 2011, 32:592-599.
22. Mukherjee B., Mayer D. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Int. J. Oncol. 2008, 33:623-629.
23. Tatevossian R.G., Lawson A.R., Forshew T., Hindley G.F., Ellison D.W., Sheer D. MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J. Cell Physiol. 2010, 222:509-514.
24. Bishop J., Simpkins J.W. Estradiol treatment increases viability of glioma and neuroblastoma cells in vitro. Mol. Cell Neurosci. 1994, 5:303-308.
25. Merritt R.L., Foran C.M. Influence of persistent contaminants and steroid hormones on glioblastoma cell growth. J. Toxicol. Environ. Health A 2007, 70:19-27.
26. Barone T.A., Gorski J.W., Greenberg S.J., Plunkett R.J. Estrogen increases survival in an orthotopic model of glioblastoma. J. Neurooncol. 2009, 95:37-48.
27. Gonzalez A., Martinez-Campa C., Mediavilla M.D., Alonso-Gonzalez C., Sanchez-Barceló, Cos S. Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. Brit. J. Cancer 2007, 97:755-760.
28. González A., Martínez-Campa C., Mediavilla M.D., Alonso-González C., Alvarez-García V., Sánchez-Barceló E.J., Cos S. Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells. Oncol. Rep. 2010, 23:1173-1178.
29. Altinoz M.A., Albayrak S.B., Karasu A., Sabanci P.A., Imer M., Bilir A. The effects of tibolone on the human primary gliobastoma multiforme cell culture and the rat C6 glioma model. Neurol. Res. 2009, 31:923-927.
30. Maltais R., Fournier M.A., Poirier D. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorg. Med. Chem. 2011, 19:4652-4668.
31. Poirier D. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. Anticancer Agents Med. Chem. 2009, 9:642-660.
32. Roy J., Maltais R., Jegham H., Poirier D. Libraries of 2β-(N-substituted piperazino)-5α-androstane-3α, 17β-diols: chemical synthesis and cytotoxic effects on human leukemia HL-60 cells and on normal lymphocytes. Mol. Divers. 2011, 15:317-339.
33. Bellavance E., Luu-The V., Poirier D. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone. J. Med. Chem. 2009, 52:7488-7502.
34. Bax D.A., Little S.E., Gaspar N., Perryman L., Marshall L., Viana-Pereira M., Jones T.A., Williams R.D., Grigoriadis A., Vassal G., Workman P., Sheer D., Reis R.M., Pearson A.D., Hargrave D., Jones C. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One 2009, 4:e5209.
35. Valera E.T., de Freitas Cortez M.A., de Paula Queiroz R.G., de Oliveira F.M., Brassesco M.S., de Oliveira F.M., Brassesco M.S., Jabado N., Faury D., Bobola M.S., Machado H.R., Scrideli C.A., Tone T.G. Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. Childs Nerv. Syst. 2009, 25:39-45.
36. Woo N.M., Salamanca C.M., Minor A., Auersperg N. An improved assay to quantitate the invasiveness of cells in modified Boyden chambers. In Vitro Cell Dev. Biol. Anim. 2007, 43:7-9.
37. Ozgen U., Savaşan S., Buck S., Ravindranath Y. Comparison of DiOC6 uptake and annexin V labeling for quantification of apoptosis in leukemia cells and non-malignant T lymphocytes from children. Cytometry 2000, 42:74-78.
38. Jansson A. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J. Steroid Biochem. Mol. Biol. 2009, 114:64-67.
39. Vihko P., Herrala A., Härkönen P., Isomaa P., Kaija H., Kurkela R., Li Y., Patrikainen L., Pulkka A., Soronen P., Törn S. Enzymes as modulators in malignant transformation. J. Steroid Biochem. Mol. Biol. 2005, 93:277-283.
40. Vihko P., Härkönen P., Soronen P., Törn S., Herrala A., Kurkela R., Pulkka A., Oduwole O., Isomaa V. 17Beta-hydroxysteroid dehydrogenases-their role in pathophysiology. Mol. Cell Endocrinol. 2004, 215:83-88.
41. Yague J.G., Lavaque E., Carretero J., Azcoitia I., Garcia-Segura L.M. Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas. Neurosci. Lett. 2004, 368:279-284.
42. Melcangi R.C., Poletti A., Cavarretta I., Celotti F., Colciago A., Magnaghi V., Motta M., Negri-Cesi P., Martini L. The 5alpha-reductase in the central nervous system: expression and modes of control. J. Steroid Biochem. Mol. Biol. 1998, 65:295-299.
43. Vasconsuelo A., Pronsato L., Ronda A.C., Boland R., Milanesi L. Role of 17β-estradiol and testosterone in apoptosis. Steroids 2011, 76:1223-1231.
44. Drury S.C., Detre S., Leary A., Salter J., Reis-Filho J., Barbashina V., Marchio C., Lopez-Knowles E., Ghazoui Z., Habben K., Arbogast S., Johnston S., Dowsett M. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr. Relat. Cancer 2011, 18:565-577.
45. Golsteyn R.M. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett. 2005, 217:129-138.
46. Jin Y.H., Yim H., Park J.H., Lee S.K. Cdk2 activity is associated with depolarization of mitochondrial membrane potential during apoptosis. Biochem. Biophys. Res. Commun. 2003, 305:974-980.
47. Droga-Mazovec G., Bojic L., Petelin A., Ivanova S., Romih R., Repnik U., Salvesen G.S., Stoka V., Turk V., Turk B. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 2008, 283:19140-19150.
48. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 39:441-446.
49. Hua H., Li M., Luo T., Yin Y., Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol. Life Sci. 2011, 68:3853-3868.
50. Yamaguchi F., Morrison R.S., Takahashi H., Teramoto A. Anti-telomerase therapy suppressed glioma proliferation. Oncol. Rep. 1999, 6:773-776.
51. Couldwell W.T., Uhm J.H., Antel J.P., Yong V.W. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 1991, 29:880-887.
52. George J., Banik N.L., Ray S.K. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int. J. Biochem. Cell Biol. 2010, 42:1164-1173.